ETFIQData as of Nov 19, 2026. · etfiq.com/funds/ibrn

IBRN Fact Sheet: iShares Neuroscience and Healthcare ETF

Share
$31.67
close, Nov 20, 2026

Over the year to Nov 19, 2026, IBRN returned +11.4% in total and charged 0.47% a year.

1-year total return
+10.0%
to Nov 20, 2026
Expense ratio
0.47%
a year
Net assets
$8.1m
on Nov 19, 2026
Net flow, last 5 trading days
$0
daily basis to Nov 19, 2026

Growth of $10,000, 1 year

IBRN $11,142 +11.4% · ACWI $10,902 +9.0% · Total return, distributions reinvested, Nov 19, 2025 to Nov 19, 2026.

Returns

WindowTotal return
1 month+0.5%
3 months−20.1%
Year to date−2.0%
1 year+10.0%
3 years+53.7%

Total return, distributions reinvested, each window to Nov 20, 2026.

Ten largest positions

HoldingWeight
BIOGEN5.42%
NEUROCRINE BIOSCIENCES5.05%
EDGEWISE THERAPEUTICS5.00%
Alkermes Public Limited Company4.78%
PRAXIS PRECISION MEDICINES4.37%
ARGENX SE ADR4.35%
AXOGEN4.34%
PTC THERAPEUTICS4.32%
DIANTHUS THERAPEUTICS3.97%
SK BIOPHARMACEUTICALS LTD3.82%

IBRN top ten by weight, 45.4% of the fund, of its 67 equity positions, from the holdings published by its issuer for Nov 13, 2026.

Facts

Holds 67 stocks in therapeutics and medical devices, 5% of its weight in S&P 500 companies · First traded Aug 26, 2022 · Benchmark Its own holdings, as of Nov 13, 2026

Source: ETFIQ, from issuer disclosures, SEC filings and exchange prices. Returns from daily closes, distributions reinvested; each number is dated beside it, and every one is on the fund’s page.Cite as: ETFIQ, IBRN Fact Sheet: iShares Neuroscience and Healthcare ETF. Data as of Nov 19, 2026. https://etfiq.com/funds/ibrn/fact-sheet/ETFIQ is an independent publisher. Not an issuer, broker or adviser. No recommendations. Printed from etfiq.com/funds/ibrn.